Eqis Capital Management Inc. reduced its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,881 shares of the medical research company’s stock after selling 888 shares during the quarter. Amgen makes up 0.5% of Eqis Capital Management Inc.’s investment portfolio, making the stock its 21st biggest holding. Eqis Capital Management Inc.’s holdings in Amgen were worth $8,239,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AMGN. Beutel Goodman & Co Ltd. acquired a new position in shares of Amgen during the 2nd quarter worth about $86,723,000. Natixis boosted its position in shares of Amgen by 2,612.1% during the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock worth $97,799,000 after acquiring an additional 510,281 shares in the last quarter. Summit Trail Advisors LLC boosted its position in shares of Amgen by 16,458.8% during the 1st quarter. Summit Trail Advisors LLC now owns 433,510 shares of the medical research company’s stock worth $434,000 after acquiring an additional 430,892 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Amgen by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after acquiring an additional 343,690 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of Amgen by 234.2% during the 2nd quarter. Bank of Nova Scotia now owns 433,450 shares of the medical research company’s stock worth $80,011,000 after acquiring an additional 303,743 shares in the last quarter. 82.38% of the stock is owned by institutional investors and hedge funds.

Amgen stock opened at $202.72 on Friday. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $131.25 billion, a PE ratio of 15.06, a PEG ratio of 1.97 and a beta of 1.40.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $5.73 billion. During the same period in the previous year, the business earned $3.27 EPS. The business’s quarterly revenue was up 4.3% on a year-over-year basis. On average, equities research analysts expect that Amgen, Inc. will post 14.02 EPS for the current year.

AMGN has been the subject of several analyst reports. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Monday, October 1st. Citigroup upped their price objective on Amgen from $188.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, July 30th. Robert W. Baird upped their price objective on Amgen from $165.00 to $179.00 and gave the stock a “neutral” rating in a research report on Monday, July 30th. Mizuho reaffirmed a “buy” rating and set a $200.00 price objective on shares of Amgen in a research report on Friday, June 22nd. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $228.00 price objective on shares of Amgen in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $204.90.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.